| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Pharsight Corporation |
| 800 West El Camino Real, Suite 200, Mountain View, CA 94040 * (650) 314-3800 |
| Business Description | The company develops and markets integrated products and services that help pharmaceutical and biotechnology companies improve the drug development process. |
| Offering Information Company has | |||
| Trading As | PHST (NASNTL) | Industry | High-Tech (SIC 7372) |
| Type of Stock Offered | Common Shares | Filing Date | 4/17/00 |
| Domestic Shares Offered | 3,000,000 | Offer Date | 8/8/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 3,000,000 | Offer Price | $10.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.700 |
| Gross Proceeds | $30,000,000 | Selling | $0.420 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 18,500,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Donaldson, Lufkin & Jenrette Securities Corp. | Lead Manager | (212) 371-0641 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| DLJDirect, Inc. | Co-manager | (800) 825-5723 |
| Wit SoundView | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 3/31/97 | 3/31/98 | 3/31/99 | 12/31/98 | 12/31/99 | ||
| Revenues | - | - | 0.000 | 1.106 | 4.085 | 2.657 | 6.252 |
| Income from Oper. | - | - | -1.974 | -4.296 | -9.773 | -7.593 | -6.809 |
| Net Income | - | - | -1.934 | -5.216 | -10.696 | -8.308 | -7.755 |
| E.P.S | - | - | -2.570 | -3.960 | -4.410 | -3.640 | -2.500 |
| Revenue Growth (%) | - | - | - | 269.349 | 135.30 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.58 | -4.08 | -5.36 | ||||
| Cash Flow - Inv. | -4.02 | -2.83 | -11.25 | ||||
| Cash Flow - Fin. | 11.05 | 11.00 | 18.11 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 23.51 | Current Assets | 21.53 | Current Ratio | 4.74 |
| Total Liab. | 24.94 | Current Liab. | 4.54 | Debt Ratio | 106.06% |
| Total Equity | -1.43 | Working Cap. | 16.99 | Debt to Equity Ratio | - |
| Cash | 5.66 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for redemption of Series C preferred stock, research and development of new and existing products and services, and working capital and other general corporate purposes including potential acquisition of products. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Sullivan & Cromwell |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Asset Management Associates 1996, L.P. | 21.70 | |
| McKesson HBOC, Inc. | 18.80 | |
| Sprout Entities, The | 12.20 | |
| Weiss, Peck & Greer Entities, The | 8.30 | |
| Note: represents ownership of 5% or more prior to the offering. | ||